Virtual consulting · Worldwide
NeuciteConsultingRequest a quote

Pharmacovigilance services for small biotech and pharma companies

For marketing authorization holders and sponsors: we draft your PV system description, PSMF and core SOPs, select and oversee vendors, and run monthly signal screening. We do not act as your QPPV.

A safety system sized to your portfolio

Every marketing authorization brings pharmacovigilance obligations, whatever the size of the company. In the EU, the holder needs a qualified person responsible for pharmacovigilance (QPPV), a pharmacovigilance system master file (PSMF) and a quality system for safety work. Our pharmacovigilance services help smaller companies build these elements in proportion to their products and markets.

The core processes are set out in the EU GVP modules and ICH guidelines. Each individual case safety report (ICSR) must be collected, assessed, coded and submitted on time. Periodic reports, such as the periodic safety update report (PSUR) or periodic benefit-risk evaluation report (PBRER), evaluate benefit-risk. Signal management looks for new or changed risks across all data sources. We write procedures for each process and test that they connect.

Many companies outsource case processing or the whole function. Pharmacovigilance outsourcing moves the work, not the accountability. The marketing authorization holder remains legally responsible and must oversee its service providers. We help you choose vendors, write the agreements, set performance indicators and design the oversight that GVP Module I expects.

Pharmacovigilance services we provide

01

PV system and PSMF design

A pharmacovigilance system description and a PSMF structured according to GVP Module II, with annexes for vendors, databases, procedures and performance. We draft; your QPPV reviews and owns the file.

02

Core safety SOPs

Procedures for case intake and processing, MedDRA coding, expedited reporting, literature screening, periodic reports, signal management and safety data exchange. Each SOP names roles and timelines so it can be audited.

03

Safety database selection

Requirements and a vendor comparison for a safety database that supports ICH E2B(R3) electronic reporting. We help define validation needs, user roles and data migration for your team or vendor to carry out.

04

Vendor selection and oversight

Request for proposal content, vendor assessment, pharmacovigilance agreements and an oversight plan with performance indicators, reconciliation checks and an audit schedule. Your organization keeps the contract and the oversight role.

05

Periodic report support

Drafting support for PSURs or PBRERs following ICH E2C(R2) and GVP Module VII, including data requests, benefit-risk sections and cumulative reviews. Your safety physician and safety team approve the final report.

06

Signal detection support

Routine screening of case data and literature for potential signals, with a documented log and rationale. Validation, prioritization and assessment decisions stay with your safety team, in line with GVP Module IX.

How we set up pharmacovigilance

Map products and obligations

We list your products, markets, authorization types and existing safety activities. From that we define the reporting rules, periodic report schedules and system elements each market requires, and where gaps exist.

Design and document

We draft the system description, master file, SOPs and agreements, and specify tools and vendors. Each document fits your organization's size, so staff can follow it and inspectors can trace it.

Hand over and support

We train your team, test the core processes end to end and hand over a complete document set. Ongoing pharmacovigilance services, such as monthly signal screening or periodic report drafting, are available by agreement.

How pharmacovigilance needs typically arrive

A

Biotech company nearing first approval

A first marketing authorization with no PV system yet

Situation
A biotech company expects its first marketing authorization in the EU. Its clinical safety team has handled trial reporting, but post-authorization obligations are new. It needs a QPPV, a PSMF and working procedures, and its application must summarize that system.
How we advise
We would map post-authorization obligations under the GVP modules, then draft the system description and master file to the GVP Module II structure. We would write core SOPs for case management, literature screening, periodic reports and signal management. We would set out what your QPPV needs from the system, such as access to data and escalation routes. You make the appointment. Finally, we would test the case flow from intake to submission.
What you receive
A draft PSMF with annexes, a core SOP set, a note on what your QPPV needs from the system and a list of gaps to close before launch.
B

Specialty pharmaceutical company

Choosing and overseeing a pharmacovigilance vendor

Situation
A specialty pharmaceutical company with several marketed products wants to outsource case processing and literature screening. Earlier vendor arrangements had unclear responsibilities. Reconciliation between partners was rarely checked. Management wants a cleaner model before contracts are renewed.
How we advise
We would define requirements and evaluation criteria, then assess shortlisted vendors on process, systems, staffing model and quality history. We would draft the pharmacovigilance agreement, setting out responsibilities, timelines and data exchange. We would build an oversight plan with performance indicators, monthly reconciliation and a vendor audit schedule. The company could then show its oversight during inspection.
What you receive
A scored vendor comparison, a draft pharmacovigilance agreement, an oversight plan with performance indicators, and a reconciliation procedure for case data between partners.
C

Small pharmaceutical sponsor

A small sponsor running safety on spreadsheets

Situation
A small company with one marketed product and an ongoing clinical trial tracks adverse events in spreadsheets. It has no validated safety database, few written procedures and no routine signal detection. Case volumes are low, but the obligations still apply.
How we advise
We would define requirements for a right-sized safety database that supports E2B(R3) reporting and compare hosted options. We would write core SOPs for case processing, expedited reporting and signal management. We would then set up a monthly signal screening routine covering the company's own cases and the literature. Review and escalation rules would keep each decision traceable.
What you receive
A database requirements document and comparison, a core SOP set, and a monthly signal screening log template with escalation criteria.

Illustrative scenarios. Each is a composite of common client situations, not a specific engagement.

Frequently asked questions

Who holds legal responsibility when we use your pharmacovigilance services?

Your organization does. The marketing authorization holder is legally responsible for pharmacovigilance and, in the EU, must have a QPPV permanently at its disposal. We do not provide a QPPV or act as one. We design systems, draft documents and support routine work, so your appointee has a system they can oversee.

What is a PSMF and do we need one?

The pharmacovigilance system master file describes your PV system in detail. Marketing authorization holders in the EU must maintain one, structured as GVP Module II describes. It must be located in the EU, kept current and available for inspection. Your marketing authorization application includes a summary of the system.

How often should signal detection run?

Frequency should match the product's risk, data volume and life cycle stage, and be justified in your procedures. Monthly screening is a common choice for small portfolios with low case volumes. It does not replace literature screening for individual case reports, which GVP Module VI expects at least weekly, or expedited reporting timelines.

What do you need from us to start?

A list of products, authorizations and markets, current safety procedures, vendor contracts, any existing master file and recent audit or inspection findings. If you hold case data, a summary of volumes and sources helps size the system. We confirm the scope in writing and send a quote.

How long does it take to set up a PV system?

It depends on the number of products and markets, whether a safety database exists and how quickly key appointments and vendor choices are made. Drafting documents is rarely the slowest step; selecting and validating tools usually is. We set out a timeline in the written quote.

Build a safety system you can stand behind

Tell us your products, markets, and current safety setup. We’ll follow up by email and send a quote that sets out the proposed work.

Neucite Consulting provides pharmacovigilance advisory and support services. We do not act as a QPPV or safety physician; the marketing authorization holder or sponsor remains legally responsible for pharmacovigilance and all regulatory reporting.